SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934
[(Amendment No. ___)]
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[X] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to ss.240.14a-11(c) or ss.240.14a-12
IGENE BIOTECHNOLOGY, INC.
--------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
-----------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which
transaction applies:_____________________
(2) Aggregate number of securities to which
transaction applies:_____________________
(3) Per unit price or other underlying value of
transaction computed pursuant to Exchange Act Rule 0-11 (set
forth the amount on which the filing fee is calculated and
state how it was determined):_____________________
(4) Proposed maximum aggregate value of transaction:________________
(5) Total fee paid:______________________
[ ] Fee previously paid with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:________________
(2) Form, Schedule or Registration Statement No.:_______________
(3) Filing Party:_______________________________
(4) Date Filed:_________________________________
<PAGE>
IGENE BIOTECHNOLOGY, INC.
-------------------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ______ __, 1997
-------------------------------------
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of IGENE
Biotechnology, Inc. (the "Company") will be held at the offices of Kimelman &
Baird, LLC, 100 Park Avenue, Suite 1101-S2, New York, New York 10017 at 10:00
a.m. local time on ____________ for the following purposes:
1. To elect (7) seven Directors.
2. To authorize and approve an amendment to the Articles of Incorporation
of the Company to increase the number of authorized shares of Common Stock to
250,000,000 shares.
3. To authorize and approve the Company's 1997 Stock Option Plan.
4. To approve the appointment of Berenson & Company as independent auditors
of the Company for the fiscal year ending December 31, 1997.
5. To transact such other business as may properly come before the meeting,
or any adjournment thereof.
Stockholders of record at the close of business on ______ __, 1997, shall
be entitled to notice of, and to vote at, the meeting.
By order of the Board of Directors
Stephen F. Hiu
President and Secretary
Dated: Columbia, Maryland
_________ __, 1997
IMPORTANT: PLEASE FILL IN, DATE, SIGN AND MAIL PROMPTLY THE ENCLOSED PROXY
IN THE POSTAGE-PAID ENVELOPE PROVIDED TO ASSURE THAT YOUR SHARES ARE REPRESENTED
AT THE MEETING.
<PAGE>
IGENE BIOTECHNOLOGY, INC.
9110 RED BRANCH ROAD
COLUMBIA, MARYLAND 21045
-----------------------------
PROXY STATEMENT
-----------------------------
The accompanying Proxy is solicited by the Board of Directors of IGENE
Biotechnology, Inc., a Maryland corporation (the "Company"), for use at the
Annual Meeting of Stockholders (the "Meeting") to be held on __________, or any
adjournment thereof, at which stockholders of record at the close of business on
________, 1997 (the "Record Date") shall be entitled to vote. The cost of
solicitation of proxies will be borne by the Company. The Company may use the
services of its Directors, officers, employees and others to solicit proxies,
personally or by telephone; arrangements may also be made with brokerage houses
and other custodians, nominees, fiduciaries and stockholders of record to
forward solicitation material to the beneficial owners of stock held of record
by such persons. The Company may reimburse such solicitors for reasonable
out-of-pocket expenses incurred by them in soliciting, but no compensation will
be paid for their services.
Each proxy executed and returned by a stockholder may be revoked at any
time before it is voted by timely submission of written notice of revocation or
by submission of a duly executed proxy bearing a later date (in either case
directed to the Secretary of the Company) or, if a stockholder is present at the
Meeting, he may elect to revoke his proxy and vote his shares personally.
There is being mailed herewith to each stockholder of record the Company's
Annual Report on Form 10-KSB for the fiscal year ended December 31, 1996. The
date of this Proxy Statement is the approximate date on which this Proxy
Statement and form of Proxy were first sent or given to stockholders.
On the Record Date, the Company had outstanding and entitled to vote with
respect to all matters to be acted upon at the meeting ________ shares of Common
Stock. Each holder of Common Stock is entitled to one vote for each share of
stock held by such holder.
On the Record Date, the Company also had outstanding and entitled to vote
with respect to all matters to be acted upon at the meeting 35,842 shares of 8%
Cumulative Preferred Stock ("Series A Preferred Stock"). Each holder of Series A
Preferred Stock is entitled to two votes for each share of Preferred Stock held
by such holder. Holders of record of outstanding Common Stock and Series A
Preferred Stock will be entitled to vote together as a single class at the
Meeting.
Pursuant to the terms of the Company's Series A Preferred Stock, as a
consequence of the non-payment of dividends on such Stock for more than the past
four consecutive dividend payment dates, the holders of Series A Preferred Stock
voting together as a single class are entitled to elect two directors, in
accordance with the procedures set forth in the Charter and by-laws of the
Company. To date, the holders of the Series A Preferred Stock have not exercised
such right. In the event they exercise their right, the Board would be expanded
to nine directors.
The presence of holders representing a majority of all the votes entitled
to be cast at the meeting will constitute a quorum at the meeting. In accordance
with Maryland law, abstentions, but not broker non-votes, are counted for
purposes of determining the presence or absence of a quorum for the transaction
of business. Each item on the agenda, except for proposal 2, must receive the
affirmative vote of a majority of the voting power voted at the meeting in order
to pass. The affirmative vote of the holders of at least two-thirds of the
outstanding voting power of the Company entitled to vote thereon is required to
authorize and approve proposal 2, the amendment to the Articles of
Incorporation. For purposes of proposal 2, abstentions and broker non-votes will
have the same effect as votes against the proposal. Abstentions and broker
non-votes are not counted in determining the votes cast with respect to any of
the matters submitted to a vote of stockholders.
It is expected that the following business will be considered at the
meeting and action taken thereon:
1. ELECTION OF DIRECTORS
Pursuant to the By-Laws of the Company, the number of Directors of the
Company has been set at seven members. It is proposed to elect seven Directors
at this Meeting to hold office for a one-year term until the 1998 Annual Meeting
of Stockholders and until their successors are duly elected and qualify. It is
intended that the accompanying form of Proxy will be voted for the nominees set
forth below, each of whom is presently a Director of the Company. If some
unexpected occurrence should make necessary, in the Board of Directors'
judgment, the substitution of some other person or persons for any of the
nominees, shares will be voted for such other person or persons as the Board of
Directors may select. The Board of Directors is not aware that any nominee may
be unable or unwilling to serve as a Director. The following table sets forth
certain information with respect to the seven nominees.
NOMINEES FOR ELECTION
NAME AGE POSITION WITH IGENE
Michael G. Kimelman 58 Chairman of the Board of Directors
Thomas L. Kempner 70 Vice Chairman of the Board of
Directors
Stephen F. Hiu 41 Director, President, Secretary,
Acting Treasurer, and Director of
Research and Development
Patrick F. Monahan 46 Director, and Director of
Manufacturing
Joseph C. Abeles 82 Director
John A. Cenerazzo 73 Director
Sidney R. Knafel 66 Director
MICHAEL G. KIMELMAN was elected a Director of the Company in February 1991
and Chairman of the Board of Directors in March 1991. He is the Managing Partner
of Kimelman & Baird, LLC. He is a founder of Blue Chip Farms, a standard bred
horse-breeding farm, and has been an officer since its inception in 1968. Mr.
Kimelman is currently a Director of the Harness Horse Breeders of New York State
and serves on the Board of the Hambletonian Society.
THOMAS L. KEMPNER is Vice Chairman of the Board of Directors and has been a
Director of the Company since its inception in October 1981. He is and has been
Chairman and Chief Executive Officer of Loeb Partners Corporation, investment
bankers, New York, and its predecessors since February 1978. He is currently a
Director of Alcide Corporation, CCC Information Services Group, Inc., Energy
Research Corp., Intermagnetics General Corp., Northwest Airlines, Inc. and Roper
Starch Worldwide, Inc.
STEPHEN F. HIU was appointed President and Treasurer in March 1991,
Secretary in July 1990, and elected a Director in August 1990. He has been
Director of Research and Development since January 1989 and, prior thereto, was
Senior Scientist since December 1985, when he joined the Company. He was a
post-doctoral Research Associate at the Virginia Polytechnic Institute and State
University, Blacksburg, Virginia, from January 1984 until December 1985. Dr. Hiu
holds a Ph.D. degree in microbiology from Oregon State University and a B.S.
degree in biological sciences from the University of California, Irvine.
PATRICK F. MONAHAN was appointed Director of Manufacturing and elected a
Director of the Company in April 1991 and has managed the Company's fermentation
pilot plant since 1982. Prior thereto, he was a technical specialist in the
fermentation pilot plant of W.R. Grace and Co. from 1975 to 1982. He received an
Associate in Arts degree in biology from Allegheny Community College and a B.S.
degree in biology with a minor in Chemistry from Frostburg State College,
Frostburg, Maryland.
JOSEPH C. ABELES, private investor, was elected Director of the Company on
February 28, 1991. Mr. Abeles serves as Director of Intermagnetics General
Corporation, Bluegreen Corporation (formerly Patten Corp.), and Ultralife
Batteries, Inc.
JOHN A. CENERAZZO was Chairman of the Board from November 1989 to April
1991. He served as President of the Company from August 1988 through September
1989 and has been a Director since September 1987. He is presently Chairman of
the Executive Committee and Director of National Penn Bank Shares, Inc. of
Boyertown, Pennsylvania, a Director of National Penn Bank, a Director of U.S.
Axle Corporation, and Chairman and a Director of InfoCore, Incorporated.
SIDNEY R. KNAFEL, a Director of the Company since 1982, has been Managing
Partner of SRK Management Company, a private investment concern, New York, since
1981, and Chairman of Insight Communications, Inc. since 1985. Mr. Knafel is
also currently a Director of BioReliance Corporation, Cellular Communications
International, Inc., CoreComm Incorporated, General American Investors Company,
Inc., NTL Incorporated and some private companies.
COMMITTEES OF THE BOARD OF DIRECTORS
The Company has two standing committees of the Board of Directors. Set
forth below is a description of the functions of those committees and the
members of the Board of Directors who serve on such committees.
AUDIT COMMITTEE
The responsibilities of the Audit Committee include recommending to the
Board of Directors the independent certified public accountants to conduct the
annual audit of the books and accounts of the Company, reviewing the proposed
scope of the audit and approving the audit fees to be paid. The Audit Committee
also reviews, with the independent certified public accountants and with the
Company's management, the adequacy and effectiveness of the internal auditing,
accounting and financial controls of the Company. There were no meetings of the
Audit Committee in 1996. The functions of the Committee were performed by the
Board during 1996.
COMPENSATION COMMITTEE
The Compensation Committee approves the salaries of all officers and
certain other employees of the Company. It also supervises the administration of
all benefit plans and other matters affecting executive compensation, subject to
further approval of the Board of Directors. The members of the Compensation
Committee during 1996 were Messrs. Thomas L. Kempner and Sidney R. Knafel. There
were no meetings of the Compensation Committee in 1996.
BOARD COMPENSATION
During 1996, Directors were not compensated for their Board or Committee
activities. The Board of Directors held 9 meetings in 1996. Each Director of the
Company attended in excess of 75% of the total number of meetings of the Board
of Directors including committee meetings for which each respective director was
a member.
EXECUTIVE COMPENSATION
The following table sets forth certain information regarding compensation
paid by the Company to its Chief Executive Officer. No other executive officer
received a salary and bonus for 1996 which exceeded $100,000.
<TABLE>
<CAPTION>
SUMMARY COMPENSATION TABLE
- -------------------------------------------------------------------------------
ANNUAL COMPENSATION
- -------------------------------------------------------------------------------
All
Other Stock Other
Name and Principal Salary Bonus Annual Options Compen
POSITION YEAR ($) ($) Compensation (#) sation
($) ($)
- ------------------ ---- ----- ----- ------------- ---------- --------
<S> <C> <C> <C> <C> <C> <C>
Dexter W. Gaston, 1996 48,494 1,418,502
Chief Executive
Officer (1)
- -------------------------------------------------------------------------------
(1) Mr. Gaston was employed by the Company from January 11, 1996 until
January 7, 1997.
</TABLE>
STOCK OPTION PLAN
Other than the 1986 Stock Option Plan (the "1986 Plan")and the proposed new
plan, the Company does not have any profit sharing, incentive compensation or
retirement plans.
The table below sets forth information with respect to stock options
granted in 1996 to the executive officer named in the Summary Compensation
Table.
<TABLE>
<CAPTION>
OPTION/SAR GRANTS IN LAST FISCAL YEAR
- -------------------------------------------------------------------------------
Individual Grants
- -------------------------------------------------------------------------------
Number Percent
of of Total
Securities Options/SARs Exercise or
Underlying Granted To Base Price Expiration
Name Option/SARs Employees In ($/Sh) Date
(a) Granted(#) Fiscal Year (d) (e)
(b) (c)
- -------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Dexter W. Gaston 1,418,502 63.9% .05 1/11/06
- -------------------------------------------------------------------------------
</TABLE>
On August 16, 1996, the Board of Directors approved the exchange of all
outstanding options under the 1986 Plan, including options held by all officers
of the Company, for new options having an exercise price of $.05 per share,
which was the market price of a share of Common Stock on that date.
The following table provides information regarding the number of shares
covered by both exercisable and unexercisable stock options for the executive
officer named in the Summary Compensation Table as of December 31, 1996, and the
value of "in-the-money" options as of that date. An option is "in-the-money" if
the per share market value of the underlying stock exceeds the option exercise
price per share. No options were exercised in 1996.
<TABLE>
<CAPTION>
AGGREGATED OPTIONS/SAR EXERCISES IN LAST FISCAL YEAR AND FY-END
OPTION/SAR VALUES
- --------------------------------------------------------------------------------------------------------------------
Number Of Value Of
Securities Unexercised In-
Underlying The-Money
Shares Value Options/SARs Options/SARs
Name Acquired Realized At Fiscal At Fiscal
(a) On Exercise ($) Year-End Year-End
(b) (c) (#) ($)
Exercisable/Unexercisable Exercisable/Unexercisable
(d) (e)
- --------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Dexter W. Gaston 0 ---- 472,834/945,668 18,913/37,827
- --------------------------------------------------------------------------------------------------------------------
(1) The value of unexercised in-the-money options at December 31, 1996, is
based on the difference between the market price on December 31, 1996
($.09 per share) and the per share option exercise price, multiplied by
the number of shares of common stock underlying such option.
</TABLE>
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information as of July 31, 1997, with
respect to beneficial ownership of shares of the Company's outstanding Common
Stock by (i) each person known to the Company to own more than five percent of
its Common Stock, (ii) each Director, and (iii) all Directors and executive
officers as a group.
Number of
Name and Address Shares Percent*
Joseph C. Abeles 12,303,804(1) 41.9%
220 E. 42nd Street, Suite 505
New York, NY 10017
John A. Cenerazzo 1,612,456(2) 7.9%
Stokesay Castle Lane
Reading, PA 19606
Stephen F. Hiu 783,833(3) 3.9%
c/o IGENE Biotechnology, Inc.
9110 Red Branch Road
Columbia, MD 21045
Thomas L. Kempner 17,033,668(4) 50.4%
c/o Loeb Partners Corporation
61 Broadway
New York, NY 10006
Michael G. Kimelman 3,049,657(5) 14.3%
c\o Kimelman & Baird, LLC
100 Park Avenue
Suite 1101-S2
New York, NY 10017
Sidney R. Knafel 15,168,144(6) 47%
c\o SRK Management
126 East 56th Street
New York, NY 10022
Patrick F. Monahan 542,000(7) 2.8%
c\o IGENE Biotechnology, Inc.
9110 Red Branch Road
Columbia, MD 21045
All Directors and Officers 50,493,562(8) 81.6%
as a Group (7 persons)
Fraydun Manocherian 3,750,000(9) 16.4%
* Under the rules of the Securities and Exchange Commission, the
calculation of the percent assumes for each person that only such
person's warrants, options or convertible notes are exercised or
converted and that no other person exercises or converts outstanding
warrants, options or convertible notes. Accordingly, these percentages
are not on a fully-diluted basis.
1 Includes 2,109,404 shares, 2,250 shares issuable upon conversion of
Series A Preferred Stock, $392,663 in demand notes convertible into
4,592,083 shares and warrants to purchase 5,583,427 shares. Also
includes 4,140 shares held by his wife and 12,500 shares issuable upon
conversion of Series A Preferred Stock held by his wife.
2 Includes 283,458 shares, warrants to purchase 713,513 shares, 32,750
shares which are subject to options currently exercisable or
exercisable within 60 days, and $49,622 in demand notes convertible
into 582,321 shares. Also includes 414 shares held by his wife.
3 Includes 500 shares held by Dr. Hiu and 783,333 shares which are
subject to options currently exercisable or exercisable within 60 days.
4 Includes 386,972 shares and warrants to purchase 212,960
shares held by Mr. Kempner; 94,000 shares held by a trust
under which Mr. Kempner is one of two trustees and the
sole beneficiary; $258,998 in demand notes convertible
into 2,797,320 shares and warrants to purchase 2,797,320
shares held by a trust under which Mr. Kempner is one of
two trustees and the sole beneficiary; 1,482,987 shares
and warrants to purchase 931,744 shares held by a trust
under which Mr. Kempner is one of two trustees and a
one-third beneficiary; $79,200 in demand notes convertible
into 1,147,670 shares and warrants to purchase 1,147,670
shares held by a trust under which Mr. Kempner is one of
two trustees and a one-third beneficiary; 182,526 shares
held by Mr. Kempner's wife; 257,880 shares held by trusts
under which Mr. Kempner is one of two trustees and whose
brothers are beneficiaries; $258,997 in demand notes
convertible into 2,797,310 shares and warrants to purchase
2,797,310 shares held in a trust under which Mr. Kempner
is one of two trustees and whose brother is beneficiary.
5 Includes 521,104 shares, warrants to purchase 1,325,674
shares and $63,070 in demand notes convertible into
804,568 shares held by Mr. Kimelman. Also includes 81,600
shares held by Kimelman & Baird, LLC, in which Mr.
Kimelman has a 50% interest, and 180,000 shares held by M.
Kimelman & Co., in which Mr. Kimelman has a 60% interest.
Also includes 136,713 shares held by his wife, in which
Mr. Kimelman disclaims beneficial ownership.
6 Includes 1,022,661 shares, warrants to purchase 3,522,835
shares, and $271,225 in demand notes convertible into
3,039,103 shares owned by Mr. Knafel. Also includes
1,022,055 shares, warrants to purchase 3,522,387 shares
and $271,225 in demand notes convertible into 3,039,103
shares held in trust for the benefit of Mr. Knafel's adult
children, as to which Mr. Knafel disclaims any beneficial
interest.
7 Includes 2,000 shares held by Mr. Monahan and 540,000 shares which are
subject to options currently exercisable or exercisable within 60 days.
8 Includes 7,768,414 shares, 1,356,083 shares which are subject to
options currently exercisable or exercisable within 60 days, unexpired
warrants to purchase 22,554,837 shares, 14,750 shares subject to the
redemption of 7,375 shares of redeemable preferred stock, and
$1,645,000 in demand notes convertible into 18,799,477 shares.
9 Includes $187,500 in demand notes convertible into 1,875,000 shares and
warrants to purchase 1,875,000 shares.
<PAGE>
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Thomas L. Kempner and Sidney R. Knafel are members of the Compensation
Committee. None of the executive officers of the Company has served on the Board
of Directors or compensation committee of any other entity that has had any of
such entity's officers serve either on the Company's Board of Directors or
Compensation Committee.
CERTAIN RELATIONSHIPS AND TRANSACTIONS
Since inception, the Company has been unable to pay its operating expenses
without outside assistance. Financing from outside sources, including
institutional lenders and customers, has not been available to the Company. Due
to the difficulty or impossibility in obtaining adequate outside financing, the
time delay and expense which would be occasioned in attempting to secure such
financing and the Company's immediate need for operating capital, since August
1993 various Directors of the Company have made periodic loans to the Company in
order to insure the Company's continued viability. The loans made by the
Directors are evidenced by demand promissory notes bearing interest at the prime
rate. All the notes are convertible into Common Stock at the market price at the
time the notes were issued. The Directors also received warrants to purchase the
number of shares of Common Stock into which the notes are convertible with an
exercise price equal to the market price at the time the note was issued.
On November 16, 1995 and December 22, 1995, the Company issued demand
promissory notes to certain directors of the Company for an aggregate
consideration of $100,000. These notes specify that at any time prior to
repayment the holder has the right to convert the note to common stock of the
Company at $.05 (the then current market price) per share. In connection with
such issuance, the holders received warrants for an equivalent number of shares
of common stock exercisable at $.05 per share.
On December 14, 1995, the shareholders of the Company ratified action taken
by the Board of Directors on April 3, 1995, with respect to the cancellation of
promissory notes and warrants issued to certain directors of the Company between
August 25, 1993 and March 7, 1995, and the conversion of these notes to common
stock of the Company at $.125 per share and warrants to purchase an equal number
of shares of common stock of the Company at $.125 per share, which was the
market price of the common stock on April 3, 1995, the date on which the action
was approved by the Board. Such warrants expire on April 3, 1998.
On February 9, 1996, and March 11, 1996, the Company issued demand
promissory notes to certain directors of the Company for an aggregate
consideration of $140,000. The notes specify that at any time prior to repayment
the holder has the right to convert the note to common stock of the Company at
$.10 per share for the note issued February 9, 1996, and at $.09 per share for
the note issued March 11, 1996 (the then current respective market prices). In
connection with such issuances, the holders received warrants for an equivalent
number of common shares at $.10 per share for the note issued February 9, 1996
and at $.09 per share for the note issued March 11, 1996.
On April 23, 1996, May 9, 1996 and June 7, 1996, the Company issued demand
promissory notes to certain Directors of the Company for an aggregate
consideration of $177,000. These notes specify that at any time prior to
repayment the holder has the right to convert the note to common stock of the
Company at $.06 per share for the notes issued April 23, 1996 and May 9, 1996,
and at $.05 for the note issued June 9, 1996 (the then current respective market
prices). In connection with such issuances, the holders received warrants for an
equivalent number of common shares at $.06 per share for the notes issued April
23, 1996 and May 9, 1996, and at $.05 per share for the note issued June 7,
1996.
On July 24, 1996 and September 24, 1996, the Company issued demand
promissory notes to certain Directors of the Company for an aggregate
consideration of $160,000. These notes specify that at any time prior to
repayment the holder has the right to convert the note to common stock of the
Company at $.115 per share for the note issued July 24, 1996, and at $.125 per
share for the note issued September 24, 1996 (the then current respective market
prices). In connection with such issuances, the holders received warrants for an
equivalent number of common shares at $.115 per share for the note issued July
24, 1996, and $.125 per share for the note issued September 24, 1996.
On November 13, 1996 and December 11, 1996, the Company issued demand
promissory notes to certain Directors of the Company for an aggregate
consideration of $140,000. These notes specify that at any time prior to
repayment the holder has the right to convert the note to common stock of the
Company at $.09 per share for the notes dated November 13, 1996 and December 11,
1996 (the then current market prices). In connection with such issuances, the
holders received warrants for an equivalent number of common shares at $.09 per
share for the notes issued November 13, 1996 and December 11, 1996.
On January 15, 1997, the Company issued demand promissory notes to certain
Directors of the Company for an aggregate consideration of $70,000. These notes
specify that at any time prior to repayment the holder has the right to convert
the note to common stock of the Company at $.07 per share (the then current
market price). In connection with such issuances, the holders received warrants
for an equivalent number of common shares at $.07 per share.
On February 24, 1997, the Company issued demand promissory notes to certain
Directors of the Company for an aggregate consideration of $100,000. These notes
specify that at any time prior to repayment the holder has the right to convert
the note to common stock of the Company at $.11 per share (the then current
market price). In connection with such issuances, the holders received warrants
for an equivalent number of common shares at $.11 per share.
On April 3, 1997, the Company issued demand promissory notes to certain
Directors of the Company for an aggregate consideration of $99,500. These notes
specify that at any time prior to repayment the holder has the right to convert
the note to common stock of the Company at $.10 (the then current market price)
per share. In connection with such issuances, the holders received warrants for
an equivalent number of common shares at $.10 per share.
On May 8, 1997, the Company issued demand promissory notes to certain
Directors of the Company for an aggregate consideration of $96,000. These notes
specify that at any time prior to repayment the holder has the right to convert
the note to common stock of the Company at $.135 (the then current market price)
per share. In connection with such issuances, the holders received warrants for
an equivalent number of common shares at $.135 per share.
As part of the Financing Transaction (as described in Proposal 2), on June
5, 1997, July 3, 1997, July 29, 1997, and September 4, 1997, the Company issued
demand promissory notes to certain Directors of the Company and to an outside
investor for an aggregate consideration of $1,000,000. These notes specify that
at any time prior to repayment the holder has the right to convert the note to
common stock of the Company at $.10 per share. In connection with such
Issuances, the holders received warrants for an equivalent number of common
shares at $.10 per share. These issuances are all part of the Bridge Loan (as
defined in Proposal 2).
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
The Company believes that during 1996 all of its officers, directors and
holders of more than 10% of its Common Stock complied with all filing
requirements under Section 16(a) of the Securities Exchange Act of 1934, except
as follows. In 1996, directors of the Company made various loans to the Company.
The loans are evidenced by demand promissory notes convertible into Common
Stock. The directors also received warrants to purchase shares of Common Stock.
In addition, in 1996, two directors of the Company (who are also officers) were
granted stock options under the Company's 1986 Plan. None of the foregoing
securities weere reported on Forms 4 or Forms 5 filed with the Securities and
Exchange Commission. In making this disclosure, the Company has relied solely on
written representations of its directors, officers and more than 10% holders and
on copies of reports that have been filed with the Securities and Exchange
Commission.
2. AMENDMENT TO ARTICLES OF INCORPORATION
INCREASING AUTHORIZED STOCK
The Company is proposing to amend Article Fifth of its Articles of
Incorporation to increase the number of authorized shares of Common Stock from
35,000,000 shares to 250,000,000 shares. This proposal will enable the Company
to complete the financing transaction (the "Financing Transaction") as described
below to enable the Company to have sufficient shares of Common Stock to be
issued or reserved for issuance pursuant to the Financing Transaction. Pursuant
to Article Fifth of its Articles of Incorporation, the Company is presently
authorized to issue 35,000,000 shares of Common Stock, par value $.01 per share,
of which on the Record Date, _______ shares were issued and outstanding. All of
the Company's unissued shares are reserved for issuance upon exercise of
presently outstanding stock options, warrants or conversion of convertible
securities. The Company is also presently authorized to issue 1,500,000 shares
of Preferred Stock, par value $.01 per share, of which on the Record Date,
223,342 shares were issued and outstanding.
It is proposed (the "Proposal") to amend Article Fifth of the Articles of
Incorporation of the Company in order to increase the authorized number of
shares of Common Stock of the Company from 35,000,000 shares, par value $.01 per
share, to 250,000,000 shares, par value $.01 per share, as follows:
ARTICLE FIFTH
The total number of shares of stock of all classes which the
Corporation has authority to issue is Two Hundred Fifty One
Million Five Hundred Thousand (251,500,000) shares divided
into Two Hundred Fifty Million (250,000,000) shares par value
of One Cent ($.01) per share of Common Stock, having an
aggregate par value of Two Million Five Hundred Thousand
Dollars ($2,500,000.00) and One Million Five Hundred Thousand
(1,500,000) shares of the par value of One Cent ($.01) per share
of Preferred Stock having an aggregate par value of Fifteen
Thousand Dollars ($15,000.00). The aggregate par value of all
shares of stock is Two Million Five Hundred Fifteen Thousand Dollars
($2,515,000.00).
The authorized number of shares of Preferred Stock will not be changed as
the result of the Proposal. The Board of Directors of the Company has
unanimously approved the adoption of the Proposal. In order for such Proposal to
be adopted there will be required a vote in favor by the holders of at least
two-thirds of the outstanding voting power of the Company entitled to be cast at
this meeting. The Board of Directors believes that it would be in the best
interests of the Company to amend Article Fifth of the Articles of Incorporation
to give effect to the Proposal.
Directors of the Company who hold approximately 39.6% of the outstanding
voting power of the Company have indicated that they intend to vote all their
shares in favor of the Proposal.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR AUTHORIZATION AND APPROVAL OF THE
AMENDMENT TO THE ARTICLES OF INCORPORATION.
The Company has been without sufficient working capital with which to fund
its operations and has been borrowing funds, from time to time, on a demand
basis from various directors of the Company. Based on the Company's operations,
it now needs the infusion of a greater amount of funds on a long term basis. Due
to the size of the proposed new financing, the Company, as described below, has
determined that it is feasible to permit all stockholders of the Company to
participate in such financing. The Company felt it was impractical to enable
stockholders to participate in the prior financings due to the smaller nature of
the prior financings and the cost and time delay involved.
Commencing in 1997, the Company has had discussions with the directors and
potential outside investors with respect to a long-term financing. In June
1997, the Company substantially completed negotiations with its directors
relating to this financing. As part of this agreement, it was determined to
offer to the stockholders of the Company the opportunity to participate in the
financing on the same terms as the directors.
Effective August 1997, various directors of the Company (Messrs. Abeles,
Cenerazzo, Kempner and Knafel) and an outside investor (collectively, the
"Investors") and the Company entered into a loan and standby purchase agreement
(the "Loan Agreement") pursuant to which the Investors agreed to make advances
to the Company from time to time in an aggregate principal amount for all such
advances outstanding not to exceed $2,000,000 at any time (the "Bridge Loan").
The $1,000,000 of loans made on and after June 5, 1997, as previously described,
are all part of the Bridge Loan. The outstanding principal amount of the Bridge
Loan bears interest at the rate of 8% per annum. The Bridge Loan is due and
payable on the first to occur of ___________, 1997, or the closing of the Rights
Offering (as described below). At the option of each Investor, all indebtedness
under the Bridge Loan will be repaid and canceled through the use of proceeds
from the Rights Offering or will be converted into Common Stock of the Company
at a conversion price of $.10 per share.
The Company has agreed to undertake a rights offering (the "Rights
Offering") in which the Company would seek to raise up to $5,000,000 by issuing
to each holder of Common Stock (including Common Stock issuable upon exercise of
outstanding convertible notes, warrants and options of the Company on an as
converted basis) one transferable right (the "Right") for each share of Common
Stock or equivalent thereof. Each Right will entitle the holder to purchase
prior to the expiration date of such Right at a subscription price of $.10 per
unit (the "Unit"), a fraction of a Unit. The fraction of the Unit which may be
purchased will vary depending on (a) the amount of funds sought to be raised by
the Company and (b) the total number of outstanding shares of Common Stock (on a
fully-diluted basis). For example, if the Company has outstanding 90,000,000
fully-diluted shares and is seeking to raise $5,000,000, each holder of a share
of Common Stock will receive 5/9th of a Unit. Each whole Unit will consist of
$.10 principal amount of unsecured promissory notes (the "New Notes") and
warrants to purchase one share of Common Stock at an exercise price of $.10 per
share (the "New Warrants").
The Investors have agreed to purchase, on a pro rata basis, enough Rights
so that the amount of Units purchased by the Investors shall total $2 million.
This will insure to the Company that the Company will receive at least $2
million of proceeds pursuant to the Rights Offering.
In consideration of the Investors committing to make the Bridge Loans,
agreeing to subscribe for Units pursuant to the Rights Offering and committing
to purchase at least $2 million of rights, the Company agreed to issue to the
Investors warrants, at an exercise price of $.10 per warrant, to purchase 10
shares of Common Stock for each $1.00 of loans made by each Investor. In
addition, the Investors agreed that all loans made by them to the Company since
November 1995 will be changed from a demand basis and will mature concurrently
with the maturity of the New Notes.
Since the stockholders of the Company will not separately vote on the
Financing Transaction, each stockholder's vote on the authorization to approve
the issuance of additional shares of Common Stock could be deemed such
stockholder's right to vote, indirectly, with respect to the Financing
Transaction. The stockholders of the Company who vote against the Proposal do
not have any appraisal rights under Maryland law with respect to their shares of
Common Stock. Pursuant to the Articles of Incorporation of the Company,
stockholders of the Company have no preemptive rights with respect to the
additional shares being authorized. The Articles of Incorporation do not require
further approval by stockholders prior to the issuance of any additional shares
of Common Stock or Preferred Stock.
The increased number of authorized shares of Common Stock will be available
for issuance by the Company, in the discretion of the Board of Directors, from
time to time. The Board of Directors will be able to issue such shares without
the time-consuming and costly need to hold a special meeting of stockholders, in
financing future growth or for other corporate purposes. Except with respect to
the Rights Offering, the Company has not entered into any specific agreements or
understandings relating to the issuance of additional shares of Common Stock;
however, the Company is receptive to all methods of financing which may be
reasonably available and to other opportunities which may arise from time to
time. The Board of Directors believes that, in the future, occasions may arise
where the time required to obtain stockholder approval might adversely delay the
Company's ability to enter into a desirable transaction. Authorized but unissued
shares of Common Stock will be issued by the Company from time to time as
appropriate and opportune situations arise.
DESCRIPTION OF UNITS
Each Unit will consist of $.10 principal amount of New Notes and a New
Warrant to purchase one share of Common Stock. The New Notes shall be general,
unsecured obligations of the Company and may be issued under an indenture with a
trustee to be selected by the Company. The New Notes will bear interest at the
rate of 8% per annum and will be due and payable five years from the date of
issuance. Interest will be payable either annually or at maturity, at the
Company's option. Beginning at the end of 1998, the New Notes will be prepayable
to the extent of 25% of the Company's net earnings determined in accordance with
generally accepted accounting principles, plus any applicable tax savings. The
prepayment right may be waived by any holder. The New Notes may be tendered at
the principal amount in payment of the exercise price of the New Warrants. The
New Notes may be prepaid by the Company at any time and from time to time. The
New Notes will not contain any negative or financial covenants. The following
will constitute defaults under the New Notes:
(a) failure to pay interest on the New Notes after the interest becomes
due and payable and continuance of such default for a period of 30
days;
(b) failure to pay all or any portion of the principal of the New Notes
when such principal becomes due and payable, whether at maturity or
otherwise and such default continuing for a period of 5 days; or
(c) certain events of bankruptcy, insolvency, or reorganization which
are voluntary or, if involuntary, continue for a period of 90 days.
Upon default the New Notes will become due and payable. Holders of a
majority of the principal amount of the New Notes outstanding will be able to
amend, modify or waive any of the provisions of the New Notes.
The New Warrants will expire ten years after issuance and will be
exercisable at an exercise price of $.10 per share. The New Warrants will be
exercisable for either cash, surrender of New Notes or by the holders electing
to receive a number of shares of Common Stock of the Company having a fair
market value equal to the difference between the fair market value of a share of
Common Stock and the exercise price. If after three years, the closing price of
a share of Common Stock is $1.00 or more, then the Company shall have the option
to redeem the New Warrants at a price of $.01 per warrant by notice given at
least 30 days prior to the redemption date. If the New Warrants are called for
redemption, they must be exercised prior to the redemption date or the right to
exercise them will be forfeited. The number of shares of Common Stock issuable
on exercise of the New Warrants and the exercise price thereof will be subject
to adjustment in the event of stock dividends, stock splits, reorganizations,
consolidations or mergers.
RISK FACTORS AFTER THE FINANCING TRANSACTION
Even if the Financing Transaction is consummated, an investment in the
Company will be subject to a number of risks, certain of which are detailed
below.
HISTORICAL NET LOSSES; STOCKHOLDERS' DEFICIT
The Company has incurred net losses since its inception. During its fiscal
year ended December 31, 1996 and six months ended June 30, 1997, the Company
incurred net losses of $776,873 and $176,238, respectively. The Company expects
to continue to incur net losses. There can be no assurance that after the Rights
Offering the Company will be able to achieve increased revenue or profitability.
At June 30, 1997, the Company had a stockholder's deficit of $3,268,303.
DEBT FINANCING; INABILITY TO SERVICE DEBT
After completion of the Financing Transaction, the Company will continue to
have substantial debt obligations of a minimum of approximately $4.6 million and
a maximum $7.6 million and will continue to have significant Preferred Stock
dividend obligations. Even if the Financing Transaction is completed, the
Company's ability to meet its debt service obligations will depend on a number
of factors, including its ability to generate operating cash flow. There can be
no assurance that targeted levels of operating cash flow will actually be
achieved. The Company's ability to generate or increase operating cash flow will
be largely dependent upon the development of its products.
LACK OF LIQUIDITY
The operating activities of the Company continue to consume net cash. The
Company believes that as a result of the proceeds of the Rights Offering, the
Company will have sufficient cash liquidity through ____. In order for cash flow
from operating activities to be sufficient to sustain the Company's operations
beyond that date, the Company will likely be required to achieve an increase in
revenue or to raise additional financing. There can be no assurance that such an
increase in revenue will occur or that it will be sufficient to maintain
adequate cash to continue operations beyond that date.
POSSIBLE DECLINE OF STOCK PRICE AFTER FINANCING TRANSACTION
The issuance of New Warrants pursuant to the Rights Offering to purchase an
aggregate of up to 50,000,000 shares of Common Stock would represent
approximately 42% of the equity of the Company on a fully diluted basis, which
could adversely affect the market price of the Common Stock.
DILUTION OF VOTING POWER OF EXISTING COMMON STOCK
Upon consummation of the Financing Transaction, the percentage of the
Company's voting securities owned by existing stockholders, other than the
Investors, could be reduced significantly on a fully diluted basis. On a fully
diluted basis, assuming exercise of all outstanding options and warrants and
conversion of notes and Preferred Stock, the outstanding voting power held by
such stockholders will be reduced from approximately 25% to approximately 18% of
the outstanding voting power of the Company.
ANTI-DILUTION PROVISIONS OF THE SERIES A PREFERRED STOCK
The Rights Offering will trigger the anti-dilution provisions of the Series
A Preferred Stock. This will dilute both the voting power of the holders of
Common Stock as well as the net tangible book value per share of Common Stock.
OWNERSHIP BY CONTROLLING STOCKHOLDERS AND POSSIBLE EFFECTS
The Investors currently hold approximately 35.8% of the outstanding Common
Stock of the Company, and approximately 75.4% on a fully diluted basis assuming
the exercise of warrants and conversion of notes.
POSSIBLE CONFLICT OF INTEREST
Following the completion of the Financing Transaction, on a fully diluted
basis, assuming exercise of all outstanding warrants and conversion of all
notes, the Investors will hold between approximately 80% and approximately 83%
of the outstanding Common Stock of the Company on a fully diluted basis,
depending on the participation of the stockholders in the Rights Offering. In
considering the recommendation of the Board with respect to the Financing
Transaction, stockholders should be aware that four of the Board's seven members
are Investors.
ABSENCE OF DIVIDENDS ON COMMON STOCK
The Company does not anticipate paying any cash dividends in the
foreseeable future. In addition, unless full cumulative dividends have been paid
on the outstanding Series A Preferred Stock, the Company will not be entitled to
pay dividends on the Common Stock.
SHARES ELIGIBLE FOR FUTURE SALE
Upon consummation of the Financing Transaction, a total of approximately 90
million additional shares of Common Stock will be issuable upon conversion of
notes and upon exercise of warrants. The conversion of such notes and the
exercise of such warrants would result in the issuance of a substantial number
of shares of Common Stock, thereby diluting the proportionate equity interests
of the holders of the Common Stock. No prediction can be made as to the effect,
if any, that future sales of shares, or the availability of shares for future
sales, will have on the market price of the Common Stock prevailing from time to
time. Sales of substantial amounts of Common Stock (including shares issued upon
the exercise of warrants or options or conversion of notes), or the perception
that such sales could occur, could adversely affect the prevailing market prices
for the Common Stock.
REASONS FOR THE FINANCING TRANSACTION AND BOARD'S RECOMMENDATION
The Board has unanimously concluded that, in its business judgment, the
Financing Transaction is the most viable financing alternative for the Company
presently available and is in the best interests of both the Company and its
stockholders. THE BOARD UNANIMOUSLY RECOMMENDS TO THE STOCKHOLDERS THAT THEY
VOTE FOR THE PROPOSAL.
In deciding to approve the Financing Transaction, the Board took into
account, among other things, the following factors:
1. ABSENCE OF OTHER ACCEPTABLE ALTERNATIVES. Prior to
negotiating the Financing Transaction, the Company explored other
sources of financing. The Company considered the Financing Transaction
to be the best alternative in that it allowed the Company to continue
to meet its working capital obligations and its debt obligations as
well as providing funds with which the Company could make capital
investments in order to enhance the long-term value of its operations.
2. CASH REQUIREMENTS. The Company has had cash commitments in
connection with its operations. The Financing Transaction will provide
an investment of at least $2 million and will result in the deferral of
payment of approximately $1,372,500 of notes. The Company believes that
the Financing Transaction, along with cash generated from operations,
will provide sufficient working capital to fund current operations and
necessary capital expenditures.
3. STRUCTURE OF THE RIGHTS OFFERING. The Board took into
account that the Rights Offering is structured in a way which will give
the stockholders of the Company the ability to acquire Units in the
Company on the same terms as the Investors. The Board also considered
that in the event that stockholders do not elect to purchase Units in
the Rights Offering, the Investors will acquire up to an aggregate of
$2 million of unsubscribed Units, guaranteeing that the Company will
receive an investment of at least $2 million in connection with the
Financing Transaction.
4. CERTAIN ADVERSE CONSEQUENCES TO STOCKHOLDERS. In
approving the Financing Transaction, the Board was cognizant of
certain adverse consequences which the Financing Transaction might
have to stockholders. In particular, the issuance of Units in the
Rights Offering and the issuance of the New Warrants would result in a
potential large increase in the Company's outstanding equity
securities.
The following table sets forth the equity ownership of the Company prior to
the consummation of the Financing Transaction and assuming exercise of
outstanding warrants and conversion of outstanding notes.
BEFORE FINANCING TRANSACTION
<TABLE>
<CAPTION>
Number of Common Percent of
Shares Assuming Equity
Exercise of Assuming
Number of Warrants and Exercise of
Common Conversion of Warrants and
Shares Percent Notes Conversion of
Notes
<S> <C> <C> <C> <C>
Stockholders
(Other than
Investors) 12,297,476 64.24% 14,962,756 23.10%
Investors 6,846,497 35.76% 49,820,571 76.90%
Total 19,143,973 100% 64,783,328 100%
Net Tangible
Book Value per Share $(0.17) $(0.05)
</TABLE>
The following table sets forth the equity ownership of the Company after
the consummation of the Financing Transaction, assuming that stockholders fully
subscribe to the Rights Offering and assuming that stockholders do not purchase
any Units upon exercise of the Rights, and that the Investors acquire $2 million
of Units.
<TABLE>
<CAPTION>
AFTER FINANCING
AFTER FINANCING TRANSACTION ASSUMING TRANSACTION ASSUMING
STOCKHOLDERS PURCHASE UNITS IN STOCKHOLDERS DO NOT
RIGHTS OFFERING(1) PURCHASE UNITS IN RIGHTS
OFFERING(1)
Percent
of Percent of
Equity Equity
Assuming Assuming
All All
Warrants Warrants
Number of Percent Exercised Number of Percent Exercised
Common of and Notes Common of and Notes
Shares Equity Converted Shares Equity Converted
<S> <C> <C> <C> <C> <C> <C>
Stock-
holders
(Other
than In-
vestors) 12,297,476 64.24% 16.67% 12,297,476 64.24% 19.70%
Investors 6,846,497 35.76% 83.33% 6,846,497 35.76% 80.30%
Total 19,143,937 100% 100% 19,143,937 100% 100%
Net
Tangible
Book
Value per
Share $(0.17) $(0.04) $(0.17) $(0.02)
(1) The effect of the transaction is to increase outstanding shares of
Common Stock, thereby producing an antidilutive effect on loss per
common share.
</TABLE>
DESCRIPTION OF CAPITAL STOCK
The summary of the terms of the capital stock of the Company set forth
below does not purport to be complete and is subject to and qualified in its
entirety by reference to the Company's Articles of Incorporation and Bylaws.
AUTHORIZED CAPITAL STOCK
The authorized capital stock of the Company consists of 35,000,000 shares
of Common Stock, and 1,500,000 shares of Preferred Stock. On ______, 1997, the
closing price of a share of Common Stock in the over-the-counter market was
$______.
COMMON STOCK
The holders of Common Stock are entitled to one vote for each share held
and have the sole right and power to vote on all matters on which a vote of
stockholders is taken, except as otherwise provided by statute and subject to
voting rights of any holders of Preferred Stock. Subject to the rights of any
holders of Preferred Stock, the holders of shares of Common Stock are entitled
to receive dividends when, as and if declared by the Board of Directors, out of
funds legally available therefor and to share pro rata in any distribution to
stockholders. Upon liquidation, dissolution, or winding up of the Company,
subject to the rights of the holders of any shares of Preferred Stock, the
holders of Common Stock are entitled to receive the net assets of the Company in
proportion to the respective number of shares held by them. The holders of
Common Stock do not have any preemptive right to subscribe for or purchase any
shares of any class of stock. The outstanding shares of Common Stock are not
subject to further call or redemption and all outstanding shares of Common Stock
are validly issued, fully paid and non-assessable.
PREFERRED STOCK
The Company is authorized to issue 1,500,000 shares of Preferred Stock.
Such shares may be issued from time to time at the discretion of the Board of
Directors, without stockholder approval. The Board of Directors is authorized to
issue such shares in different series and with respect to each series to
determine the dividend rate, the redemption provisions, voting rights,
conversion provisions, liquidation preferences and such other rights and
privileges not in conflict with the Company's Articles of Incorporation and any
qualifications, limitations or restrictions on such shares.
The Company has designated 1,050,000 shares of its authorized Preferred
Stock as Series A Preferred Stock. Such shares pay a cumulative 8% annual
dividend ($.64 per share).
The stated value of the Series A Preferred Stock is $8.00 per share. Each
share of Series A Preferred Stock may be converted into Common Stock at rate of
$4.00 per share (such conversion ratio may be adjusted due to stock splits,
stock dividends or issuance of rights or warrants).
Holders of the Series A Preferred Stock are entitled to vote on all matters
requiring stockholder approval as one class with the holders of Common Stock.
Each holder of Series A Preferred Stock is entitled to a number of votes equal
to the number of shares of Common Stock into which such holder of Series A
Preferred Stock would be entitled to convert his or her shares as of the Record
Date. Holders are currently entitled to two votes per share of Series A
Preferred Stock.
Pursuant to the Articles of Incorporation as amended, the Series A
Preferred Stock is entitled to special voting privileges in the event of a
dividend default. A dividend default occurs if dividends have not been paid on
the Series A Preferred Stock for four consecutive dividend payment dates. In
such a case, the holders of Series A Preferred Stock, as a class, are entitled
to elect two directors.
While dividends have not been paid on the Series A Preferred Stock for more
than the past four quarters, the holders of the Series A Preferred Stock have
not exercised their special voting privileges.
Shares of Series A Preferred Stock are redeemable for cash in whole or in
part at the option of the Company at any time at the stated value, plus accrued
and unpaid dividends. The Series A Preferred Stock is mandatorily redeemable in
October 2002.
In May 1988, the Company and a holder of the Series A Preferred Stock
entered into an agreement under which the mandatory redemption rights were
waived as to 187,500 shares of Series A Preferred Stock. The holder of those
shares also waived its voting rights.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Company's Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1996, and Quarterly Report on Form 10-QSB for the six months ended
June 30, 1997, copies of which accompany this Proxy Statement, are incorporated
herein by reference.
All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") subsequent to
the date of this Proxy Statement and prior to the meeting shall be deemed to be
incorporated by reference herein and to be a part hereof from the date of the
filing of such reports and documents. Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for the purposes of this Proxy Statement to the extent
that a statement contained herein or in any other subsequently filed document
which also is incorporated or deemed to be incorporated by reference herein
modifies or supersedes such statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part
of this Proxy Statement.
The Company will provide, without charge, to each person to whom a copy of
this Proxy Statement is delivered, upon the written or oral request of such
person and by first class mail or other equally prompt means within one business
day of receipt of such request, a copy of any or all of the documents
incorporated herein by reference (other than exhibits, unless such exhibits are
specifically incorporated herein by reference). Requests should be directed to:
Investor Relations, IGENE Biotechnology, Inc., 9110 Red Branch Road, Columbia,
Maryland 21045.
The Company is subject to the informational requirements of the Exchange
Act and, in accordance therewith, files reports, proxy or information statements
and other information with the Commission. Such reports, proxy or information
statements, exhibits and other information filed by the Company with the
Commission can be inspected and copied at the public reference facilities
maintained by the Company at Room 1024, Judiciary Plaza, 450 Fifth Street, N.W.,
Washington, D.C. 20549, and at the Regional Offices of the Commission at 7 World
Trade Center (13th Floor), New York, New York 10048 and Northwestern Atrium
Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661- 2511.
Copies of such materials can be obtained by mail from the Public Reference
Section of the Commission at Room 1024, Judiciary Plaza, 450 Fifth Street, N.W.,
Washington, D.C. 20549, and its public reference facilities in New York, New
York and Chicago, Illinois, at prescribed rates. The Commission maintains an
Internet web site that contains reports, proxy and information statements and
other information regarding issuers who file electronically with the Commission.
FINANCIAL INFORMATION
Financial information for the Company for the fiscal year ended December
31, 1996, is included in the Company's Annual Report on Form 10-KSB, a copy of
which accompanies this Proxy Statement. In addition, set forth below are the Pro
Forma Balance Sheets, and accompanying notes, which give effect to the Financing
Transaction and Rights Offering. Pro Forma statements of operations have not
been presented, since the transaction does not affect net loss.
<PAGE>
<TABLE>
<CAPTION>
IGENE BIOTECHNOLOGY, INC.
BALANCE SHEETS
AFTER FINANCING TRANSACTION ASSUMING STOCKHOLDERS PURCHASE ALL UNITS IN
RIGHTS OFFERING
AS OF JUNE 30, 1997 AND DECEMBER 31, 1996
Historical Proforma Proforma Historical Proforma Proforma
June 30, Adjustments June 30, December 31, Adjustments December 31,
1997 1997 1996 1996
(Unaudited) (Unaudited) (Audited) (Unaudited)
ASSETS
<S> <C> <C> <C> <C> <C> <C>
Current assets:
Cash and Cash equivalents $ 101,911 $6,750,000 $6,851,911 $ 41,339 $ 7,000,000 $7,041,339
Accounts receivable 15,309 ---- 15,309 9,996 ---- 9,996
Due from stockholders 40,097 ---- 40,097 16,870 ---- 16,870
Supplies ---- ---- 0 6,126 ---- 6,126
Equipment held for resale 283,762 ---- 283,762 ---- ---- ----
Deferred costs 45,925 ---- 45,925 ---- ---- ----
Prepaid expenses 1,219 ---- 1,219 4,652 ---- 4,652
----------- ------------ ----------- -------- ------------ -----------
Total current assets 488,223 6,750,000 7,238,223 78,983 7,000,000 7,078,983
----------- ------------ ----------- --------- ------------ -----------
Other assets:
Property and equipment, net 33,955 ---- 33,955 19,471 ---- 19,471
Security deposits 10,600 ---- 10,600 10,600 ---- 10,600
----------- ------------- ----------- --------- ------------- ----------
Total assets $532,778 $6,750,000 $7,282,778 $109,054 $7,000,000 $7,109,054
----------- ------------- ----------- --------- ------------- ----------
LIABILITIES,
REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and
accrued expenses $ 396,130 $ ---- $ 396,130 $ 300,799 ---- $ 300,799
Debenture Interest payable 45,000 ---- 45,000 45,000 ---- 45,000
Promissory notes payable 1,372,500 (1,372,500) --- 717,000 (717,000) ---
----------- -------------- ----------- ---------- ----------- ---------
Total current liabilities 1,513,630 (1,372,500) 441,130 1,062,799 ---- 345,799
Long-term liabilities:
Promissory notes payable ---- 5,122,500 5,122,500 ---- 5,717,000 5,717,000
Variable rate subordinated
debenture 1,500,000 ---- 1,500,000 1,500,000 ---- 1,500,000
------------ ----------- ----------- ----------- ----------- ------------
Total liabilities 3,313,630 4,750,000 8,063,630 2,562,799 5,717,000 7,562,799
------------ ----------- ----------- ----------- ----------- ------------
Redeemable preferred stock 487,451 ---- 487,451 475,982 ---- 475,982
------------ ----------- ----------- ----------- ----------- ------------
Stockholders' deficit:
Preferred stock 1,875 ---- 1,875 1,875 ---- 1,875
Common stock 186,711 200,000 386,711 186,311 200,000 386,311
Additional paid-capital 18,049,351 1,800,000 19,849,351 17,971,220 1,800,000 19,771,220
Deficit (21,506,240) ---- (21,506,240) (21,089,133) ---- (21,089,133)
--------------- ------------ ------------ ------------ ------------ ------------
Total stockholders' deficit (3,268,303) 2,000,000 (1,268,303) (2,929,727) 2,000,000 (929,727)
--------------- ------------ ------------ ------------ ------------ ------------
Total liabilities, redeemable
preferred stock and
stockholders' deficit $ 532,778 $ 6,750,000 $7,282,778 $ 109,054 $7,717,000 $7,109,054
--------------- ------------- ------------ ------------ ------------- ------------
</TABLE>
<PAGE>
NOTES TO PROFORMA BALANCE SHEETS:
The above proforma balance sheets provide information about the impact of
the Financing Transaction by showing how it might have affected historical
financial statements if the Transaction had been consummated at an earlier time.
Proforma statements of operations have not been presented, since the
Transaction does not affect net loss. The Financing Transaction, under the
assumptions described below, increases common shares outstanding by 20,000,000
shares and increases fully diluted common shares outstanding by 87,500,000 and
90,000,000 shares, respectively, as of June 30, 1997 and December 31, 1996,
thereby producing an antidilutive effect on loss per common share.
$250,000 of Bridge Financing was outstanding as of June 30, 1997, and is
included in the historical balance sheet as of June 30, 1997.
The above unaudited proforma balance sheets have been prepared under the
following assumptions:
1. That the Investors convert all financing under the Bridge
Loan into Common Stock of the Company at $0.10 per share, or
20,000,000 shares; and
2. That all stockholders, including the Investors, exercise all
Rights issued to them under the Rights Offering.
<PAGE>
<TABLE>
<CAPTION>
IGENE BIOTECHNOLOGY, INC.
BALANCE SHEETS
AFTER FINANCING TRANSACTION ASSUMING STOCKHOLDERS DO NOT PURCHASE ANY
UNITS IN RIGHTS OFFERING
AS OF JUNE 30, 1997 AND DECEMBER 31, 1996
Historical
Historical Proforma Proforma December 30, Proforma Proforma
June 30, 1997 Adjustments June 30, 1997 1996 Adjustments December 31, 1996
(Unaudited) (Unaudited) (Audited) (Unaudited)
ASSETS
------ ------------- ----------- ------------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C>
Current assets:
Cash and cash equivalents $101,911 $1,750,000 $1,851,911 41,339 $2,000,000 $2,041,339
Accounts receivable 15,309 --- 15,309 9,996 --- 9,996
Due from stockholders 40,097 --- 40,097 16,870 --- 16,870
Supplies --- --- 0 6,128 --- 6,126
Equipment held for resale 283,762 --- 283,782 --- --- ---
Deferred costs 45,925 --- 45,925 --- --- ---
Prepaid expenses 1,219 --- 1,219 4,652 --- 4,652
---------- ----------- ------------ -------- ---------- -----------
Total current assets 488,223 1,750,000 2,238,223 78,983 2,000,000 2,078,983
Other assets:
Property and equipment, net 33,955 --- 33,955 19,471 --- 19,471
Security deposits 10,600 --- 10,600 10,600 --- 10,600
Total assets $ 532,778 $1,750,000 $2,282,778 $109,054 $2,000,000 $2,109,054
=========== ============= =========== ========== ============ ============
LIABILITIES,
REDEEMABLE PREFERRED STOCK AND
STOCKHOLDER'S DEFICIT
Current liabilities
Accounts payable and
accrued expenses $ 396,130 $ ---- $396,130 $300,799 $---- $300,799
Debenture interest payable 45,000 ---- 45,000 45,000 ---- 45,000
Promissory notes payable 1,372,500 (1,372,500) --- 717,000 (717,000) ---
----------- -------------- --------- --------- ---------- ----------
Total current liabilities 1,813,630 (1,372,500) 441,130 1,062,799 ---- 345,799
Long-term liabilities:
Promissory notes payable --- 3,122,500 3,122,500 2,717,00 2,717,000
Variable rate subordinated
debenture 1,500,000 --- 1,500,000 1,500,000 ---- 1,500,000
------------ -------------- ----------- ---------- ---------- ----------
Total liabilities 3,313,630 1,750,000 5,063,630 2,562,799 2,717,000 4,562,799
------------ -------------- ----------- ---------- ---------- -----------
Redeemable preferred stock 487,451 --- 487,451 475,982 ----- 475,982
------------ -------------- ----------- ---------- ---------- -----------
Stockholders' deficit:
Preferred stock 1,875 --- 1,875 1,875 ----- 1,875
Common stock 186,711 --- 186,711 186,311 - 186,311
Additional paid-in capital 18,049,351 --- 18,049,351 17,971,220 ---- 17,971,220
Deficit (21,506,240) --- (21,506,240)(21,089,133) ---- (21,089,133)
------------- ------------ ------------ -------------- ----------- -------------
Total stockholders' deficit (3,268,303) --- (3,268,303) (2,929,727) ---- (2,929,727)
------------- ------------- ------------- ------------- ---------- -------------
Total liabilities,
redeemable preferred
stock and stockholders'
deficit $ 532,778 $1,750,000 $2,282,778 $109,054 $2,717,000 $2,109,054
============== ============== ============= ============ =========== ============
</TABLE>
<PAGE>
NOTES TO PROFORMA BALANCE SHEETS:
The above proforma balance sheets provide information about the impact of the
Financing Transaction by showing how it might have affected historical financial
statements if the Transaction had been consummated
at an earlier time.
Proforma statements of operations have not been presented, since the Transaction
does not affect net loss. The Financing Transaction, under the assumptions
described below, does not affect common shares outstanding and increases fully
diluted common shares outstanding by 35,000,000 and 40,000,000 shares,
respectively, as of June 30, 1997 and December 31, 1996, thereby producing an
antidilutive effect on loss per common share.
$250,000 of Bridge Financing was outstanding as of June 30, 1997 and is included
in the historical balance sheet as of June 30, 1997.
The above unaudited proforma balance sheets have been prepared under the
following assumptions:
1. That the Bridge Loan will be repaid and canceled through the
use of proceeds from the Rights Offering.
2. That the investors exercise only enough Rights so that the
amount of Units purchased shall total $2 million, and
3. That other stockholders do not purchase any Units.
<PAGE>
RIGHTS OFFERING
THIS PROXY STATEMENT SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY THE UNITS TO BE ISSUED PURSUANT TO THE RIGHTS
OFFERING. A REGISTRATION STATEMENT RELATING TO SUCH UNITS WILL BE FILED BY THE
COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION. UNITS TO BE ISSUED IN
CONNECTION WITH THE RIGHTS OFFERING WILL NOT BE SOLD PRIOR TO THE TIME THE
REGISTRATION STATEMENT BECOMES EFFECTIVE.
CERTAIN INCOME TAX CONSEQUENCES
The following summary of federal income tax consequences is based on
current law, is for general information only and is not based upon or supported
by a ruling of the Internal Revenue Service (the "Service"). The tax treatment
of a holder of Rights or Units acquired on exercise of a Right may vary
depending upon his particular situation. Certain holders (including insurance
companies, tax-exempt organizations, financial institutions, broker-dealers,
foreign corporations and persons who are not citizens or residents of the United
States) may be subject to special rules not discussed below. EACH HOLDER SHOULD
CONSULT HIS OWN TAX ADVISOR AS TO THE PARTICULAR TAX CONSEQUENCES TO HIM OF
RECEIVING, HOLDING, EXERCISING AND DISPOSING OF THE RIGHTS OR UNITS, INCLUDING
THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, FOREIGN AND PENDING TAX LAWS.
RIGHTS
RECEIPT OF RIGHTS. Pursuant to Section 305(a) of the Internal Revenue Code
of 1986, as amended (the "Code"), a holder should not recognize income for
federal income tax purposes by reason of the receipt of a Right, and the Company
intends to so treat the distribution of Rights as a nontaxable distribution.
If the Service were to take a contrary position with respect to this
matter, by deeming the distribution of Rights to constitute a taxable
distribution, a holder receiving a Right would recognize a dividend, taxable as
ordinary income, in an amount equal to the fair market value of the Right
received, but only to the extent of the current and accumulated earnings and
profits of the Company. To the extent the deemed distribution exceeds the
current and accumulated earnings and profits of the Company, such excess would
be treated first as a nontaxable recovery of adjusted tax basis in the security
with respect to which the Right was distributed and then as gain from the sale
or exchange of such security. A holder's tax basis in a Right received in a
taxable distribution would equal the fair market value of the Right as of the
date of distribution of the Right (the "Distribution Date").
Under the Company's intended treatment (i.e. a nontaxable distribution), if
a Right is exercised, the tax basis of the Right in the hands of a holder will
be determined by allocating the holder's tax basis in his securities with
respect to which the Right was distributed between such securities and the
Right, in proportion to their relative fair market values on the Distribution
Date. If, however, the fair market value of the Right on the Distribution Date
is less than 15% of the fair market value of the securities with respect to
which the Right was distributed, the holder's tax basis in the Right will be
deemed to be zero unless the holder affirmatively elects, in accordance with
Treasury Regulations, to apportion his tax basis in accordance with the
preceding sentence. The holding period of a Right will include the holding
period for the securities with respect to which the Right was distributed.
EXERCISE OF RIGHTS. No gain or loss will be recognized by a holder of
Rights upon exercise of the Rights for cash. A holder who pays the subscription
price ("Subscription Price") through surrender of notes may recognize gain to
the extent the Subscription Price exceeds the holder's tax basis in the notes
surrendered therefor. Additionally, a holder who pays the Subscription Price
through surrender of notes may be required to recognize as ordinary income any
accrued interest on the surrendered notes that has not been taken into account
previously as interest income for tax purposes. The adjusted tax basis of a
holder of Units acquired upon exercise of Rights will be equal to the sum of the
holder's adjusted tax basis in the exercised Rights and the Subscription Price.
The holding period for Units acquired upon exercise of Rights will commence on
the date of such exercise.
EXPIRATION OF RIGHTS WITHOUT EXERCISE. If a holder of a Right allows it to
expire without exercise, the expiration will be treated as a sale or exchange of
the Right on the expiration date. Because an unexercised Right should be treated
upon expiration as having a zero basis in the hands of the holder of the Right,
such holder should not recognize loss as a result thereof.
ADJUSTMENT TO THE TERMS OF A RIGHT. An adjustment to the Subscription Price
of a Right, or the failure to make such an adjustment (and possibly an
adjustment to the number of Units purchasable upon the exercise of the Right or
the failure to make such an adjustment), in certain circumstances may result in
a distribution that could be taxable as a dividend under the Code to the holder
of the Right or the Units. Alternatively, a modification of the terms of a Right
may be treated as a taxable exchange of the Right for a new right to purchase
Units, with the holder recognizing gain or loss (as discussed above), even
though no cash may have been distributed to the holder.
UNITS
DISPOSITION OF UNITS. The sale or other disposition of Units acquired on
exercise of a Right will result in the recognition of gain or loss by the holder
of such Units in an amount equal to the difference between the amount realized
and the holder's adjusted tax basis in the Units. Gain or loss will be capital
gain or loss if the Units were held as a capital asset, and will be long-term
capital gain or loss if the Units have a holding period for tax purposes of more
than one year.
POTENTIAL LIMITATIONS ON USE OF LOSS CARRYFORWARDS
In general, upon a change of ownership, Section 382 of the Code limits the
amount of a loss corporation's taxable income that could be offset annually by
its carryforwards of net operating losses (and certain "built-in" losses that
are economically accrued but not recognized at the time of a change of
ownership) to an amount equal to the product obtained by multiplying the
aggregate value of such corporation's capital stock immediately prior to the
requisite change of ownership by the federal long-term tax-exempt interest rate.
A change of ownership occurs and Section 382 of the Code will apply if, within a
three year "testing period," there is more than a 50 percentage point increase
in the capital stock of the loss corporation held by persons who own (actually
or constructively) at least five percent in value of the loss corporation's
stock (with persons who separately are less than five percent stockholders
generally being treated in the aggregate as a single stockholder). Except in
limited circumstances, options to acquire stock will be treated as if they had
been exercised, on an option-by-option basis, if such treatment results in the
requisite change of ownership.
BACKUP WITHHOLDING AND REPORTING REQUIREMENTS
A holder of Rights or Units may be subject to backup withholding at the
rate of 31% with respect to dividends paid on and gross proceeds from the sale
or redemption of the Rights or Units, unless the holder (a) is a corporation or
comes within certain other exempt categories and, when required, demonstrates
this fact, or (b) provides a correct taxpayer identification number, certifies
as to no loss of exemption from backup withholding and otherwise complies with
applicable requirements of the backup withholding rules. Holders of Rights or
Units who do not provide the Company with their correct taxpayer identification
number may be subject to penalties imposed by the Service. Any amount withheld
under these rules will be creditable against the holder's federal income tax
liability.
The Company will report to the holders of Rights and Units and to the
Service, the amount of any "reportable payments" and any amount withheld with
respect to the Rights and Units during each calendar year.
THE FOREGOING DISCUSSION OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES IS FOR
GENERAL INFORMATION ONLY. ACCORDINGLY, EACH HOLDER OF RIGHTS AND UNITS SHOULD
CONSULT HIS OWN TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF THE
ACQUISITION, OWNERSHIP AND DISPOSITION OF THE RIGHTS AND UNITS, INCLUDING THE
APPLICABILITY AND EFFECT OF STATE, LOCAL, FOREIGN AND PENDING TAX LAWS.
NON-APPROVAL OF FINANCING TRANSACTION
In the event that the Financing Transaction is not approved by the
stockholders, the Company will seek other financing and attempt to seek other
terms for restructuring the Bridge Loan. If the Proposal is not approved, the
Bridge Loan and the promissory notes issued by the Company since 1995 would
immediately become due and payable.
USE OF PROCEEDS
The Company anticipates using the cash proceeds received by it from the
Financing Transaction for working capital and general corporate purposes.
THE BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE FOR THE PROPOSAL.
<PAGE>
3. PROPOSAL TO APPROVE
THE 1997 STOCK OPTION PLAN
On _________, 1997, the Board of Directors of the Company adopted the 1997
Stock Option Plan (the "Plan"), subject to approval by the stockholders of the
Company. Incentive stock options, intended to qualify under Section 422 of the
Code, and nonqualified stock options may be granted under the Plan. The
following is a summary of the material provisions of the Plan.
PURPOSE
The purpose of the Plan is to advance the interests of the Company by
encouraging and enabling the acquisition of a larger personal proprietary
interest in the Company by directors, key employees, consultants and independent
contractors who are employed by, or perform services for, the Company and its
subsidiaries and upon whose judgment and keen interest the Company is largely
dependent for the successful conduct of its operations. It is also expected that
the opportunity to acquire such a proprietary interest will enable the Company
and its subsidiaries to attract and retain desirable personnel, directors and
other service providers.
ADMINISTRATION
The Plan is administered by a Committee (the "Committee") of the Board of
Directors, which must consist of two or more directors of the Company, each of
whom must be a "Non-Employee Director" within the meaning of Rule 16b-3 under
the 1934 Act and an "outside director" within the meaning of Section 162(m) of
the Code. The Committee may grant options to key employees, directors,
consultants and independent contractors to the Company. The term of each option
may not exceed ten years from the date of grant. The exercise price of an option
shall be determined by the Committee, but in the case of an incentive stock
option (as described below), the per share exercise price may not be less than
100% of the fair market value of a share of Common Stock on the date of grant.
The options generally vest at a rate determined by the Committee at the time of
grant.
Determinations of the Committee as to any question which may arise with
respect to the interpretation of the provisions of the Plan and Options are
final. The Committee may authorize and establish such rules, regulations and
revisions thereof not inconsistent with the provisions of the Plan, as it may
deem advisable to make the Plan and Options effective, or provide for their
administration, and may take such other action with regard to the Plan and
Options as it deems desirable to effectuate their purpose.
MAJOR PROVISIONS OF THE PLAN
TYPES OF OPTIONS TO BE GRANTED. Under the Plan, the Committee may grant
either an "incentive stock option" within the meaning of Section 422 of the Code
or options which do not satisfy Section 422 of the Code ("non-qualified stock
options"). Options with respect to which no designation is made by the Committee
are deemed to be incentive stock options to the extent they meet the
requirements for incentive stock options. No option which is intended to qualify
as an incentive stock option may be granted under the Plan to any individual
who, at the time of such grant, is not an employee of the Company.
ELIGIBILITY. The potential recipients of Options under the Plan are
directors of the Company, key employees of the Company, and consultants and
independent contractors used by the Company (collectively, the "Eligible
Participants") each individually as determined by the Compensation Committee in
its sole discretion. At September __, 1997, approximately ___ persons were
eligible to participate in the Plan. No Option which is intended to qualify as
an incentive stock option may be granted under this Plan to any employee who, at
the time the Option is granted, owns shares possessing more than ten percent of
the total combined voting power or value of all classes of stock of the Company,
unless the exercise price under such Option is at least 110% of the fair market
value of a share of Common Stock on the date such Option is granted and the
duration of such Option is no more than five years.
SHARES OF COMMON STOCK SUBJECT TO THE PLAN. The Board of Directors proposes
for stockholder approval that the Plan provide that the number of shares of
Common Stock that may be the subject of Options may not exceed 2,000,000 in the
aggregate, which Common Stock may be held in treasury or authorized but
unissued. The maximum number of shares which may be the subject of options
granted to any individual during any calendar year shall not exceed 1,000,000
shares. If any Option shall expire, be canceled or terminate for any reason
without having been exercised in full, the unpurchased shares subject thereto
may again be made subject to Options under the Plan; however, any option granted
to a "covered employee" as defined under Section 162(m) of the Code which is
canceled or repriced shall continue to be counted against the maximum number of
shares subject to options granted to such employee, in accordance with Section
162(m) of the Code.
GRANT OF OPTIONS. The Committee, in its sole discretion (subject to the
Plan) determines the number of shares of Common Stock subject to each Option
granted to any eligible participant under the Plan. The terms of the Plan do not
prohibit the issuance of Options at different times to the same person.
OPTION EXERCISE PRICE AND DURATION. The Committee fixes the price per share
of the Common Stock to be purchased pursuant to the exercise of any Option;
however, the per share exercise price under an incentive stock option may not be
less than the Fair Market Value (as defined in the Plan) of a share of Common
Stock on the day on which the Option is granted. The Committee fixes the
duration of an Option up to a maximum of ten years from the date of grant.
CONSIDERATION FOR OPTIONS. The Company must obtain such consideration for
the grant of an Option as the Committee in its discretion may request.
EXERCISE OF OPTIONS. An Option, once granted, will be exercisable by the
holder (or if deceased, by his estate) at such rate and times as may be fixed by
the Committee. Options become exercisable in full (but in no event until
stockholder approval of the Plan) upon (i) the holder's retirement on or after
his 65th birthday, (ii) the disability or death of the holder (subject to the
provisions on termination of employment), or (iii) under special circumstances
which in the opinion of the Committee warrant special consideration. Options may
not be transferred nor assigned by the holder except that the Committee may
authorize a transfer of a non-qualified option to certain family members or
trusts or to other entities as may be permitted by the Committee, subject to
such terms and conditions as are approved by the Committee.
TERMINATION OF OPTIONS. Options terminate at the end of the tenth business
day following the holder's cessation of service as an employee, director,
consultant or independent contractor. This period is extended to three months in
the case of the holder's retirement on or after attaining age 65 or disability,
and to six months in the case of the holder's death (in which case the Option is
exercisable by the holder's estate). If the employment or service of an Option
holder is terminated due to a violation of his duties, the Option terminates
immediately. In no event may any option be exercised after the expiration of the
term of the option.
PAYMENT FOR AND ISSUANCE OF SHARES. Payment for the shares purchased
pursuant to the exercise of an Option shall be made in full at the time of the
exercise of the Option, in cash, by check, by delivery of previously-owned
shares of Common Stock (beneficially owned for at least six months and valued at
their Fair Market Value as of the date of the exercise), or by such other
methods as the Committee may permit from time to time. The Plan contains
standard provisions to assure that any exercise of an Option or the issuance of
shares pursuant thereto will not violate applicable securities and income tax
withholding laws.
ADJUSTMENT OF SHARES. The Plan contains usual anti-dilution provisions in
the event of certain corporate transactions.
AMENDMENT AND TERMINATION OF THE PLAN. The Board of Directors or the
Committee may at any time withdraw or from time to time amend the Plan and any
Options not theretofore granted. With respect to any outstanding Option, the
Board of Directors or the Committee, with the consent of the affected holder of
an Option, may at any time withdraw or from time to time amend the Plan and the
terms and conditions of any outstanding Option. Notwithstanding the foregoing,
any amendment by the Board of Directors or the Committee which would increase
the number of shares of Common Stock issuable under Options, increase the number
of Options which may be granted to any individual during a calendar year, or
change the class of persons to whom Options may be granted, shall be subject to
the approval of the stockholders of the Company. No Option shall be granted
under the Plan after __________, 2007.
FEDERAL INCOME TAX CONSIDERATIONS
INCENTIVE STOCK OPTIONS. An employee will not recognize income upon the
grant or exercise of an incentive stock option. If an employee disposes of the
shares acquired upon exercise of an incentive stock option at least two years
after the date the Option was granted and at least one year after the date the
shares are transferred to him upon the exercise of an Option, the employee will
realize long-term capital gain in an amount equal to the excess, if any, of his
selling price for the shares over the exercise price. In such case, the Company
will not be entitled to any tax deduction. If an employee disposes of the shares
acquired upon the exercise of an incentive stock option prior to the expiration
of two years from the date the Option was granted, or one year from the date the
shares are transferred to him, any gain realized will be taxable at such time as
follows: (1) as ordinary income to the extent of the difference between the
Option exercise price and the lesser of (a) the fair market value of the shares
on the date the shares were transferred to him or (b) the amount realized on
such disposition, and (2) as capital gain to the extent of any excess, which
gain shall be treated as short-term or long-term capital gain depending upon the
employee's holding period. In such case, the Company may claim an income tax
deduction for the amount taxable to the employee as ordinary income. The
difference between the fair market value of the shares at the time the incentive
stock option is exercised and the exercise price will constitute an item of
adjustment, for purposes of determining alternative minimum taxable income, and
may under certain circumstances be subject, in the year in which the Option is
exercised, to the alternative minimum tax.
If an individual uses shares of Common Stock of the Company that he owns to
pay, in whole or in part, the exercise price under an incentive stock option,
(a) the individual's holding period for the newly-issued shares equal in number
to the surrendered shares (the "exchanged shares") shall include the period
during which the surrendered shares were held, (b) the employee's basis in such
exchanged shares will be the same as his basis in the surrendered shares, and
(c) no gain or loss will be recognized by the employee on the exchange of the
surrendered shares for the exchanged shares. Further, the employee will have a
zero basis in any additional shares received over and above the exchanged
shares. However, if an employee tenders shares acquired pursuant to the exercise
of an incentive stock option to pay all or part of the exercise price under an
incentive stock option, such tender will constitute a disposition of such shares
for purposes of the one-year (or two-year) holding period requirement applicable
to incentive stock options and such tender will be treated as a taxable exchange
if such holding period has not been met.
NON-QUALIFIED STOCK OPTIONS. A holder will not recognize any income at the
time a non-qualified stock option is granted. If the holder is not a Director,
officer, or principal stockholder (i.e., an owner of more than ten percent of
the Common Stock of the Company), he will recognize ordinary income at the time
he exercises a non-qualified stock option in a total amount equal to: (1) in the
case of Options which the holder exercises with cash, the excess of the then
fair market value of the shares acquired over the exercise price and (2) in the
case of Options which a holder exercises by tendering previously owned shares,
the then fair market value of the number of shares issued in excess of the fair
market value of the number of shares surrendered upon such exercise. Section 83
of the Code generally provides that if a Director, officer, or principal
stockholder receives shares pursuant to the exercise of a non-qualified stock
option, he is not required to recognize income until the date on which he can
sell such shares at a profit without being subject to liability under Section
16(b) of the 1934 Act. In general, pursuant to regulations under Section 16(b)
of the 1934 Act the restriction on selling such shares at a profit will be
considered to have lapsed six months after the later of the original grant date
of the option or the option holder's intervening purchase of shares or other
equity securities of the Company in a transaction that is subject to the
short-swing profit recovery provisions of Section 16(b) of the 1934 Act.
Alternatively, a Director, officer or principal stockholder who would not
otherwise be subject to tax on the value of his shares as of the date they were
acquired can file a written election, within 30 days after the shares are
transferred to him, pursuant to Section 83(b) of the Code, to be taxed as of the
date of transfer. In either case, the Director, officer, or principal
stockholder would realize income equal to the amount by which the fair market
value, at the time the income is recognized, of the shares acquired pursuant to
the exercise of such option exceeds the price paid for such shares.
All income realized upon the exercise of any non-qualified stock option
will be taxed as ordinary income. The Company may claim an income tax deduction
(if applicable tax withholding rules are satisfied) for the amount taxable to a
holder in the same year as those amounts are taxable to a holder. Shares issued
upon the exercise of a non-qualified stock option are generally eligible for
capital gain or loss treatment upon any subsequent disposition. Generally, a
holder's holding period will commence from the date such shares are issued to
him, and his basis in such shares will equal their fair market value as of that
date, but the holding period of a Director, officer, or principal stockholder
begins on the date he recognizes income with respect to such shares, and his
basis in the shares will be equal to the greater of the then fair market value
of the shares or the amount paid for such shares. If an individual uses shares
of Common Stock that he owns to exercise a non-qualified stock option, (a) the
individual's holding period for the newly-issued shares equal in number to the
surrendered shares (the "exchanged shares") shall include the period during
which the surrendered shares were held, (b) the holder's basis in such exchanged
shares will be the same as his basis in the surrendered shares, and (c) no gain
or loss will be recognized by the holder on the exchange of the surrendered
shares for the exchanged shares.
SECTION 280G OF THE CODE. In addition to the Federal income tax
consequences discussed above, Section 280G of the Code provides that if an
officer, stockholder or highly compensated individual receives a payment which
is in the nature of compensation and which is contingent upon a change in
control of the employer, and such payment equals or exceeds three times his Base
Salary (as hereinafter defined), then any amount received in excess of Base
Salary shall be considered an "excess parachute payment." An individual's Base
Salary is equal to his average annual compensation over the five-year period (or
period of employment, if shorter) ending with the close of the individual's
taxable year immediately preceding the taxable year in which the change in
control occurs. In addition to any income tax which would otherwise be owed on
such payment, the individual will be subject to an excise tax equal to 20% of
such excess payment (and the Company will not be allowed any deduction which
might otherwise have been allowed for such excess payment). If the taxpayer
establishes, by clear and convincing evidence, that the amount received is
reasonable compensation for past or future services, all or a portion of such
amount shall be deemed not to be an excess parachute payment.
Section 280G provides that payments made pursuant to a contract entered
into within one year of the change in control are presumed to be parachute
payments unless the individual establishes, by clear and convincing evidence,
that such contract was not entered into in contemplation of a change in control.
In addition, the General Explanation of the Tax Reform Act of 1984 prepared by
the Staff of the Joint Committee on Taxation indicates that the grant of an
Option within one year of the change in control or the acceleration of an Option
because of a change in control may be considered a parachute payment, in an
amount equal to the value of the Option or the value of the accelerated portion
of the Option, as the case may be. Pursuant to proposed regulations, the
acceleration of a non-qualified stock option because of a change in control will
be considered a parachute payment. Even if the grant of an Option, if any,
within one year of the change in control or the acceleration of an Option, if
any, is not a parachute payment for purposes of Section 280G, the exercise of an
Option granted within one year of the change in control or the exercise of the
accelerated portion of an Option may result in a parachute payment, in an amount
equal to the excess of the fair market value of the shares received upon
exercise of the Option over the exercise price. Payments received for the
cancellation of an Option, if any, because of a change in control may also
result in parachute payments.
SECTION 162(M) OF THE CODE. Section 162(m) of the Code generally limits the
Company's tax deduction with respect to certain compensation paid to its Chief
Executive Officer and the four other most highly compensated executive officers
to $1 million per year, per officer. Income pursuant to options under the Plan
may be treated as compensation that is subject to the $1 million limitation on
the Company's tax deduction under Section 162(m) of the Code. However, income
pursuant to options under the Plan with an exercise price that is equal to the
fair market value of the stock on the date of grant is intended to qualify as
"performance-based" compensation that is not subject to the deduction limitation
under Section 162(m) of the Code.
The foregoing summarizes all material Federal income tax consequences;
however, reference is made to the applicable provisions of the Code. Each
participant may wish to discuss specific questions with his own tax adviser or
attorney. In addition, there may be tax considerations under state and local
laws applicable to participants.
OPTIONS GRANTED
Pursuant to the 1986 Plan, all current directors and executive officers as
a group have been granted Options for a total of 1,356,083 shares and all
employees as a group have been granted Options for a total of 1,670,750 shares.
No options have been granted under the Plan.
VOTE REQUIRED FOR APPROVAL
The affirmative vote of a majority of the votes cast on the proposal to
approve the Plan is required for approval of the Plan.
THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE FOR APPROVAL OF THE
PLAN.
4. APPOINTMENT OF INDEPENDENT AUDITORS
The Board of Directors of the Company has selected Berenson & Company as
independent auditors of the Company for the fiscal year ending December 31,
1997. A representative of Berenson & Company is not expected to be present at
the meeting.
THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE FOR APPROVAL OF
THE APPOINTMENT OF BERENSON & COMPANY AS THE COMPANY'S AUDITORS.
5. OTHER MATTERS
STOCKHOLDER PROPOSALS
Proposals of stockholders intended to be presented at the Company's 1998
Annual Meeting of Stockholders must be received by the Company on or prior to
______ __, 1998, to be eligible for inclusion in the Company's Proxy Statement
and form of Proxy to be used in connection with such meeting.
OTHER BUSINESS
At the date of this Proxy Statement, the only business which the Board of
Directors intends to present or knows that others will present at the Meeting is
that hereinabove set forth. If any other matter or matters are properly brought
before the meeting, or any adjournment thereof, it is the intention of the
persons named in the accompanying form of Proxy to vote the Proxy on such
matters in accordance with their judgment.
Stephen F. Hiu
President and Secretary
Dated: __________ ___, 1997
<PAGE>
IGENE BIOTECHNOLOGY, INC.
1997 Annual Meeting of Stockholders - _________, 1997
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
P The undersigned stockholder of IGENE BIOTECHNOLOGY, INC., a Maryland
R corporation, hereby appoints Stephen F. Hiu, Michael G. Kimelman and
O Thomas L. Kempner, and each of them the proxies of the undersigned with
X full power of substitution to vote at the Annual Meeting of Stockholders
Y of the Company to be held at 10:00 a.m. on ___________, 1997, and at any
adjournment or adjournments thereof (the "Meeting"), with all the power
which the undersigned would have if personally present, hereby revoking
any proxy heretofore given. The undersigned hereby acknowledges
receipt of the proxy statement for the Meeting and instructs the proxies
to vote as directed on the reverse side.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" ALL PROPOSALS.
CONTINUED AND TO BE SIGNED ON REVERSE SIDE
SEE REVERSE
SIDE
<PAGE>
THIS PROXY, WHEN PROPERLY SIGNED, WILL BE VOTED IN THE MANNER DIRECTED. IF
NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF ALL
NOMINEES LISTED BELOW, FOR THE AMENDMENT TO THE ARTICLES OF INCORPORATION,
FOR THE APPROVAL OF THE 1997 STOCK OPTION PLAN, FOR THE RATIFICATION OF THE
APPOINTMENT OF BERENSON & COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31,
1997 AND IN THE DISCRETION OF THE PROXY HOLDERS AS TO ANY OTHER MATTERS
WHICH MAY PROPERLY COME BEFORE THE MEETING.
1. To elect seven nominees 4. To ratify the appointment of Berenson &
for directors: Company as independent auditors for the
Nominees: Michael G. Kimelman, fiscal year ending December 31, 1997
Thomas L. Kempner, Stephen F.Hiu,
Patrick F. Monahan, Joseph C.
Abeles, John A. Cenerzaao FOR AGAINST ABSTAIN
and Sidney R. Knafel / / / / / /
/ / FOR / /WITHHELD 5. With discretionary authority upon
/ / such other matters as may properly
- ----------------------------------- come before the Meeting.
For all nominees except as noted above
Please sign exactly as your name
appears on this proxy card. When
2. To approve the Amendment to the signing as attorney, executor,
Articles of Incorporation trustee or guardian, please give
FOR AGAINST ABSTAIN your full title.
/ / / / / /
3. To approve the 1997 Stock Option Plan
FOR AGAINST ABSTAIN
/ / / / / /
Signature__________ Date_________
